183 related articles for article (PubMed ID: 35979662)
1. Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers.
Montero-Conde C; Leandro-García LJ; Martínez-Montes ÁM; Martínez P; Moya FJ; Letón R; Gil E; Martínez-Puente N; Guadalix S; Currás-Freixes M; García-Tobar L; Zafon C; Jordà M; Riesco-Eizaguirre G; González-García P; Monteagudo M; Torres-Pérez R; Mancikova V; Ruiz-Llorente S; Pérez-Martínez M; Pita G; Galofré JC; Gonzalez-Neira A; Cascón A; Rodríguez-Antona C; Megías D; Blasco MA; Caleiras E; Rodríguez-Perales S; Robledo M
Clin Transl Med; 2022 Aug; 12(8):e1001. PubMed ID: 35979662
[TBL] [Abstract][Full Text] [Related]
2. Thyroid carcinoma-featured telomerase activation and telomere maintenance: Biology and translational/clinical significance.
Yuan X; Yuan H; Zhang N; Liu T; Xu D
Clin Transl Med; 2022 Nov; 12(11):e1111. PubMed ID: 36394204
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
Yuan X; Larsson C; Xu D
Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
[TBL] [Abstract][Full Text] [Related]
5. Telomerase reverse transcriptase haploinsufficiency and telomere length in individuals with 5p- syndrome.
Du HY; Idol R; Robledo S; Ivanovich J; An P; Londono-Vallejo A; Wilson DB; Mason PJ; Bessler M
Aging Cell; 2007 Oct; 6(5):689-97. PubMed ID: 17875000
[TBL] [Abstract][Full Text] [Related]
6. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
[TBL] [Abstract][Full Text] [Related]
7. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant
Fotouhi O; Ghaderi M; Wang N; Zedenius J; Kjellman M; Xu D; Juhlin CC; Larsson C
Epigenetics; 2019 Dec; 14(12):1224-1233. PubMed ID: 31322481
[TBL] [Abstract][Full Text] [Related]
9. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
Stögbauer L; Stummer W; Senner V; Brokinkel B
Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
[TBL] [Abstract][Full Text] [Related]
10. Severe growth defect in mouse cells lacking the telomerase RNA component.
Niida H; Matsumoto T; Satoh H; Shiwa M; Tokutake Y; Furuichi Y; Shinkai Y
Nat Genet; 1998 Jun; 19(2):203-6. PubMed ID: 9620783
[TBL] [Abstract][Full Text] [Related]
11. Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors.
Kim HS; Lee HS; Nam KH; Choi J; Kim WH
Anticancer Res; 2015 Jun; 35(6):3501-10. PubMed ID: 26026117
[TBL] [Abstract][Full Text] [Related]
12. Telomere length assessment and molecular characterization of TERT gene promoter in periampullary carcinomas.
Gregório C; Thakur S; Camara Rivero R; Márcia Dos Santos Machado S; Cuenin C; Carreira C; White V; Cree IA; Vukojevic K; Glavina Durdov M; Bersch Osvaldt A; Ashton-Prolla P; Herceg Z; Talukdar FR
Gene; 2023 Jul; 873():147460. PubMed ID: 37150235
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutations in telomere biology.
Heidenreich B; Kumar R
Mutat Res Rev Mutat Res; 2017; 771():15-31. PubMed ID: 28342451
[TBL] [Abstract][Full Text] [Related]
14. Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma.
Wang N; Kjellin H; Sofiadis A; Fotouhi O; Juhlin CC; Bäckdahl M; Zedenius J; Xu D; Lehtiö J; Larsson C
Oncotarget; 2016 Apr; 7(16):21332-46. PubMed ID: 26870890
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta.
Novakovic B; Napier CE; Vryer R; Dimitriadis E; Manuelpillai U; Sharkey A; Craig JM; Reddel RR; Saffery R
Mol Hum Reprod; 2016 Nov; 22(11):791-799. PubMed ID: 27604461
[TBL] [Abstract][Full Text] [Related]
16. Telomerase gene mutations and telomere length shortening in patients with idiopathic pulmonary fibrosis in a Chinese population.
Dai J; Cai H; Zhuang Y; Wu Y; Min H; Li J; Shi Y; Gao Q; Yi L
Respirology; 2015 Jan; 20(1):122-8. PubMed ID: 25346280
[TBL] [Abstract][Full Text] [Related]
17. A telomerase-independent component of telomere loss in chromatin assembly factor 1 mutants of Arabidopsis thaliana.
Jaške K; Mokroš P; Mozgová I; Fojtová M; Fajkus J
Chromosoma; 2013 Aug; 122(4):285-93. PubMed ID: 23564254
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma.
Boscolo-Rizzo P; Giunco S; Rampazzo E; Brutti M; Spinato G; Menegaldo A; Stellin M; Mantovani M; Bandolin L; Rossi M; Del Mistro A; Tirelli G; Dei Tos AP; Guerriero A; Niero M; Da Mosto MC; Polesel J; De Rossi A
J Cancer Res Clin Oncol; 2020 Feb; 146(2):381-389. PubMed ID: 31960186
[TBL] [Abstract][Full Text] [Related]
19. Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinoma.
Jendrzejewski J; Tomsic J; Lozanski G; Labanowska J; He H; Liyanarachchi S; Nagy R; Ringel MD; Kloos RT; Heerema NA; de la Chapelle A
J Clin Endocrinol Metab; 2011 Nov; 96(11):E1876-80. PubMed ID: 21900378
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]